Eatontown, NJ, November 26, 2014. Avet Pharmaceuticals Inc. (“Avet”) announced the immediate availability of Rizatriptan immediate-release tablets in 5 and 10 mg strengths. This launch adds to Avet’s robust portfolio of generic oral solid products. Rizatriptan is the AB rated generic equivalent to the anti-migraine drug Maxalt®*. It is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. According to IMS data for the twelve-months ended August 2014, the U.S. market for Rizatriptan immediate-release tablets is approximately $55.6 million.